nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

1. Nanotechnology: Concepts and Potential Applications in Medicine

verfasst von : Luiziana Cavalcante Costa Fernandes, Karina Alexandre Barros Nogueira, Jéssica Roberta Pereira Martins, Elias Santos, Paulo George Cavalcante de Freitas, Beatriz Alexandre Barros Nogueira, Giovanni Loureiro Raspantini, Raquel Petrilli, Josimar O. Eloy

Erschienen in: Nanomaterials and Nanotechnology

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Nanocarriers have gained enormous highlight as a platform for drug delivery. These systems are often prepared with a variety of either natural or synthetic lipid, polymeric and inorganic materials. Preparation protocols include different bottom-up and top-down strategies, depending on the physicochemical characteristics of the raw materials and drugs. Moreover, the physicochemical properties of nanocarriers can be investigated with different analytical techniques, including dynamic light scattering, electron microscopy, differential scanning calorimetry, etc. The great interest for these nanocarriers is owing to their advantages for drug delivery, such as the protection of the encapsulated drug against degradation, the possibility of sustained release, higher solubility of lipophilic drugs, improved pharmacokinetics, prolonged circulation, passive targeting to solid tumors, based on the enhanced permeability and retention (EPR) effect. Also, these nanocarriers can be actively targeted to disease sites through functionalization using moieties such as peptides, folate, monoclonal antibodies and others. Altogether, these characteristics lead to improved efficacy of drugs in the treatment of a variety of diseases, with reduced side effects. Furthermore, nanocarriers have been successfully demonstrated as effective for diagnosis of diseases and have been also employed as theranostic agents. The application of nanocarriers for both treatment and diagnosis of diseases has been thoroughly investigated both in vitro, in cell culture experiments and in vivo, using xenograft animal models, for cancer, for example. However, nanocarriers are promising for application in other conditions, including inflammatory, infectious and degenerative diseases. Finally, many clinical trials have confirmed the efficacy and safety of nanocarriers, and nowadays, there is a variety of formulations available in the market, particularly liposomes. In the next years, many more nanocarriers are expected to move from bench to bedside, particularly in the field of cancer therapy.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Nächstes Kapitel Biopolymers for Eco-Safe Remediation

Abd Elrahman AA, Mansour FR (2019) Targeted magnetic iron oxide nanoparticles: preparation, functionalization and biomedical application. J Drug Deliv Sci Technol 52(January):702–712. https://doi.org/10.1016/j.jddst.2019.05.030CrossRef

Abedi M, Sadat S, Abedanzadeh M, Borandeh S (2019) Citric acid functionalized silane coupling versus post-grafting strategy for dual PH and saline responsive delivery of cisplatin by Fe 3 O 4/Carboxyl functionalized mesoporous SiO₂ hybrid nanoparticles: a-synthesis. Mater Sci Eng C 104(June):109922. https://doi.org/10.1016/j.msec.2019.109922CrossRef

Adnan NNM, Cheng YY, Ong NMN, Kamaruddin TT, Rozlan E, Schmidt TW, Duong HTT, Boyer C (2016) Effect of gold nanoparticle shapes for phototherapy and drug delivery. Polym Chem 7(16):2888–2903. https://doi.org/10.1039/c6py00465bCrossRef

Ajnai G, Chiu A, Kan T, Cheng CC, Tsai TH, Chang J (2014) Trends of gold nanoparticle-based drug delivery system in cancer therapy. J Exp Clin Med 6(6):172–178. https://doi.org/10.1016/j.jecm.2014.10.015CrossRef

Alibolandi M, Abnous K, Mohammadi M, Hadizadeh F, Sadeghi F, Taghavi S, Reza M, Ramezani M (2017) Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation. J Controlled Release 264(August):228–236. https://doi.org/10.1016/j.jconrel.2017.08.030CrossRef

Almouazen E, Bourgeois S, Boussaïd A, Valot P, Malleval C, Fessi H, Nataf S, Brianc S (2012) Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages. 430:207–15. https://doi.org/10.1016/j.ijpharm.2012.03.025

Anarjan FS (2019) Active targeting drug delivery nanocarriers: Ligands. Nano-Structures Nano-Objects 19:100370CrossRef

Arranja AG, Pathak V, Lammers T, Shi Y (2017) Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res 115:87–95. https://doi.org/10.1016/j.phrs.2016.11.014CrossRef

Asgari S, Saberi AH, McClements DJ, Lin M (2019) Microemulsions as nanoreactors for synthesis of biopolymer nanoparticles. Trends Food Sci Technol 86:118–130. https://doi.org/10.1016/j.tifs.2019.02.008CrossRef

Attarad A, Hira Zafar MZ, ul Haq I, Phull AR, Ali JS, Hussain A (2016) Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. Nanotechnol Sci Appl 9:49–67. https://doi.org/10.2147/NSA.S99986

Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F (2017) Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett 190(April):64–83. https://doi.org/10.1016/j.imlet.2017.07.015CrossRef

Bajgelman MC (2019) Chapter 8. principles and applications of flow cytometry. In: Data processing handbook for complex biological data sources. Elsevier Inc. https://doi.org/10.1016/B978-0-12-816548-5.00008-3

Baksi R, Singh DP, Borse SP, Rana R, Sharma V, Nivsarkar M (2018) In vitro and in vivo anticancer efficacy potential of quercetin loaded polymeric nanoparticles. Biomed Pharmacother 106(July):1513–1526. https://doi.org/10.1016/j.biopha.2018.07.106CrossRef

Bavli Yaelle, Winkler Ilan, Mae Bing, Roffler Steve, Cohen Rivka, Szebeni Janos (2019) Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. J Controlled Release 306(June):138–148. https://doi.org/10.1016/j.jconrel.2019.06.007CrossRef

Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology : new insights into their cellular reduction. 11(05):127–52. https://doi.org/10.1016/S1387-2656(05)11004-7

Biosciences BD (2002) Introduction to flow cytometry : a learning guide. https://www.bdbiosciences.com/en-us

Borenfreund E, Puerner JA (1985) Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24(2–3):119–124. https://doi.org/10.1016/0378-4274(85)90046-3CrossRef

Brannon-Peppas Lisa, Blanchette James O (2012) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–212CrossRef

Breznan D, Das D, MacKinnon-Roy C, Simard B, Kumarathasan P, Vincent R (2015) Non-specific interaction of carbon nanotubes with the resazurin assay reagent: impact on in vitro assessment of nanoparticle cytotoxicity. Toxicol In Vitro 29(1):142–147. https://doi.org/10.1016/j.tiv.2014.09.009CrossRef

Bruch GE, Fernandes LF, Bassi BLT, Alves MTR, Pereira IO, Frézard F, Massensini AR (2019) Liposomes for drug delivery in stroke. Brain Res Bull 152(June):246–256. https://doi.org/10.1016/j.brainresbull.2019.07.015CrossRef

Callender SP, Mathews JA, Kobernyk K, Wettig SD (2017) Microemulsion utility in pharmaceuticals: implications for multi-drug delivery. Int J Pharm 526(1–2):425–442. https://doi.org/10.1016/j.ijpharm.2017.05.005CrossRef

Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR (2017) Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem 25(5):606–635. https://doi.org/10.2174/0929867324666171009120154CrossRef

Ceborska M (2017) Folate appended cyclodextrins for drug, DNA, and SiRNA delivery. Eur J Pharm Biopharm 120(September):133–145. https://doi.org/10.1016/j.ejpb.2017.09.005CrossRef

Cencig S, Coltel N, Truyens C, Carlier Y (2012) Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 40(6):527–532. https://doi.org/10.1016/j.ijantimicag.2012.08.002CrossRef

Chountoulesi M, Pippa N, Pispas S, Chrysina ED, Forys A, Trzebicka B, Demetzos C (2018) Cubic lyotropic liquid crystals as drug delivery carriers: physicochemical and morphological studies. Int J Pharm 550(1–2):57–70. https://doi.org/10.1016/j.ijpharm.2018.08.003CrossRef

Courtois P, Rorat A, Lemiere S, Guyoneaud R, Attard E, Levard C, Vandenbulcke F (2019) Ecotoxicology of silver nanoparticles and their derivatives introduced in soil with or without sewage sludge: a review of effects on microorganisms, plants and animals. Environ Pollut 253:578–598. https://doi.org/10.1016/j.envpol.2019.07.053CrossRef

Crucho CIC (2015) Stimuli-responsive polymeric nanoparticles for nanomedicine. ChemMedChem 10(1):24–38. https://doi.org/10.1002/cmdc.201402290CrossRef

Crucho CIC, Barros MT (2017) Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater Sci Eng C 80:771–784. https://doi.org/10.1016/j.msec.2017.06.004CrossRef

Cun X, Ruan S, Chen J, Zhang L, Li J, He Q, Gao H (2016) A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan. Acta Biomater 31:186–196. https://doi.org/10.1016/j.actbio.2015.12.002CrossRef

Cysteine R, Yang Y, Niu X, Zhang Q, Hao L, Ding Y (2012) The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic. Am J Med Sci 344(3):199–205. https://doi.org/10.1097/MAJ.0b013e31823e62e5CrossRef

Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Knüchel R, Kiessling F, Lammers T (2019) Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 138:302–325. https://doi.org/10.1016/j.addr.2019.01.005CrossRef

Dash TK, Konkimalla VB (2012) Polymeric modification and its implication in drug delivery : poly- ε-caprolactone (PCL) as a model polymer. https://doi.org/10.1021/mp3001952

de Araújo RF, de Araújo AA, Pessoa JB, Freire Neto FP, da Silva GR, Leitão Oliveira ALCS, de Carvalho TG et al (2017) Anti-inflammatory, analgesic and anti-tumor properties of gold nanoparticles. Pharmacol Rep 69(1):119–129. https://doi.org/10.1016/j.pharep.2016.09.017

de Oliveira LC, Taveira JF, Souza LG, Marreto RN, Lima ME, Taveira FS (2012) Aplicações das nanopartículas lipídicas no tratamento de tumores sólidos: revisão de literatura. Rev Bras Cancerologia 58(45):695–70112

Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 108(7):2909–2914. https://doi.org/10.1073/pnas.1018892108CrossRef

Dissanayake S, Denny WA, Gamage S, Sarojini V (2017) Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Controlled Release 250:62–76CrossRef

Donahue N, Acar H, Wilhelm S (2019) Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev

Du Qiang, Jiang Lei, Wang Xiao Qian, Pan Wei, She Fei Fei, Chen Yan Ling (2014) Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma. Asian Pac J Cancer Prev 15(8):3747–3752. https://doi.org/10.7314/APJCP.2014.15.8.3747CrossRef

Dunigan DD, Waters SB, Owen TC (1995) Aqueous soluble tetrazolium/formazan MTS as an indicator of NADH- and NADPH-dependent dehydrogenase activity. Biotechniques 19(4):640–649

Edwards KA, Baeumner AJ (2006) Analysis of liposomes. Talanta 68(5):1432–1441. https://doi.org/10.1016/j.talanta.2005.08.031CrossRef

Eisenbrand G, Pool-Zobel B, Baker V, Balls M, Blaauboer BJ, Boobis A, Carere A et al (2002) Methods of in vitro toxicology. Food Chem Toxicol 40(2–3):193–236. https://doi.org/10.1016/S0278-6915(01)00118-1CrossRef

Eloy J, Petrilli R, Lopez R, Lee R (2015) Stimuli-responsive nanoparticles for SiRNA delivery. Curr Pharm Des 21(29):4131–4144. https://doi.org/10.2174/1381612821666150901095349CrossRef

Eloy JO, Petrilli R, Topan JF, Antonio HMR, Barcellos JPA, Chesca DL, Serafini LN, Tiezzi DG, Lee RJ, Marchetti JM (2016) Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B 141:74–82. https://doi.org/10.1016/j.colsurfb.2016.01.032CrossRef

Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Maldonado J (2017a) Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eur J Pharm Biopharm 115:159–167CrossRef

Eloy JO, Petrilli R, Trevizan L, Chorilli M (2017b) Immunoliposomes: a review on functionalization strategies and targets for drug delivery. Colloids Surf B 159:454–467CrossRef

Epple M (2018) Review of potential health risks associated with nanoscopic calcium phosphate. Acta Biomater 77:1–14. https://doi.org/10.1016/j.actbio.2018.07.036CrossRef

Eriksson S, Nylén U, Rojas S, Boutonnet M (2004) Preparation of catalysts from microemulsions and their applications in heterogeneous catalysis. Appl Catal A 265(2):207–219. https://doi.org/10.1016/j.apcata.2004.01.014CrossRef

Ernsting MJ, Mami M, Roy A, Li S (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Realese 23(1):1–7. https://doi.org/10.1038/jid.2014.371CrossRef

Farran B, Pavitra E, Kasa P, Peela S, Seeta G, Raju R (2019) Cytokine and growth factor reviews folate-targeted immunotherapies: passive and active strategies for cancer. Cytokine Growth Factor Rev 45(January):45–52. https://doi.org/10.1016/j.cytogfr.2019.02.001CrossRef

Fisichella M, Dabboue H, Bhattacharyya S, Saboungi M, Salvetat J, Hevor T, Guerin M (2009) Mesoporous silica nanoparticles enhance MTT formazan exocytosis in HeLa cells and astrocytes. Toxicol In Vitro 23(4):697–703. https://doi.org/10.1016/j.tiv.2009.02.007CrossRef

Fornaguera C, García-Celma MJ (2017) Personalized nanomedicine: a revolution at the nanoscale. J Personalized Med 7(4):14–21. https://doi.org/10.3390/jpm7040012CrossRef

Funk D, Schrenk HH, Frei E (2007) Serum albumin leads to false-positive results in the XTT and the MTT assay. Biotechniques 43(2):178–186. https://doi.org/10.2144/000112528CrossRef

Ganesan P, Narayanasamy D (2017) Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain. Chem Pharm 6(May):37–56. https://doi.org/10.1016/j.scp.2017.07.002CrossRef

Garcês A, Amaral MH, Lobo JMS, Silva AC (2018) Formulations based on Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci 112(November 2017):159–67. https://doi.org/10.1016/j.ejps.2017.11.023

Gardner ER, William D, Figg WD (2008) Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. 862:213–18. https://doi.org/10.1016/j.jchromb.2007.12.013

Geszke-Moritz M, Moritz M (2016) Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C 68:982–994. https://doi.org/10.1016/j.msec.2016.05.119CrossRef

Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M, Farahmand M, Javanmard D, Jalal Kiani S, Esghaei M (2019) Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles : another emerging application of nanomedicine. 4:1–10

Gordillo-Galeano A, Mora-Huertas CE (2018) Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 133(October):285–308. https://doi.org/10.1016/j.ejpb.2018.10.017CrossRef

Gormley AJ, Greish K, Ray A, Robinson R, Gustafson JA, Ghandehari H (2011) Gold nanorod mediated plasmonic photothermal therapy: a tool to enhance macromolecular delivery. Int J Pharm 415(1–2):315–318. https://doi.org/10.1016/j.ijpharm.2011.05.068CrossRef

Gosenca M, Bešter-Rogač M, Gašperlin M (2013) Lecithin based lamellar liquid crystals as a physiologically acceptable dermal delivery system for ascorbyl palmitate. Eur J Pharm Sci 50(1):114–122. https://doi.org/10.1016/j.ejps.2013.04.029CrossRef

Gunasekaran T, Nigusse T, Dhanaraju MD (2011) Silver nanoparticles as real topical bullets for wound healing. J Am Coll Clin Wound Spec 3(4):82–96. https://doi.org/10.1016/j.jcws.2012.05.001CrossRef

Guo C, Wang J, Cao F, Lee RJ, Zhai G (2010) Lyotropic liquid crystal systems in drug delivery. Drug Discovery Today 15(23–24):1032–1040. https://doi.org/10.1016/j.drudis.2010.09.006CrossRef

Gutjahr A, Phelip C, Coolen AL, Monge C, Boisgard AS, Paul S, Verrier B (2016) Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. Vaccines 4(4):1–16. https://doi.org/10.3390/vaccines4040034CrossRef

Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. 6(September):319–27

Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38. https://doi.org/10.1016/j.addr.2016.04.025CrossRef

Holder AL, Goth-goldstein R, Lucas D, Koshland CP (2012) Particle-induced artifacts in the MTT and LDH viability assays

Hussain Z, Arooj M, Malik A, Hussain F, Safdar H, Khan S (2018) Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics : new developments in overcoming drug resistance and optimizing anticancer efficacy. 46:1015–1025

Iijima S (1991) Helical microtubules of graphitic carbon. Lett Nat 353:412–414CrossRef

Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. 116–120

Jain K, Mehra NK, Jain NK (2014) Potentials and emerging trends in nanopharmacology. Curr Opin Pharmacol 15(1):97–106. https://doi.org/10.1016/j.coph.2014.01.006CrossRef

Jeong Y-I, Na H-S, Seo D-H, Kim D-G, Lee H-C, Jang M-K, Na S-K, Roh S-H, Kim S-I, Nah J-W(2008) Nanoparticles and its antibacterial activity. 352:317–323. https://doi.org/10.1016/j.ijpharm.2007.11.001

Kawabata H(2019) Transferrin and transferrin receptors update. Free Radical Biol Med 133(June 2018):46–54. https://doi.org/10.1016/j.freeradbiomed.2018.06.037

Khawar IA, Kim JH, Kuh HJ (2015) Improving drug delivery to solid tumors: priming the tumor microenvironment. J Controlled Release 201:78–89. https://doi.org/10.1016/j.jconrel.2014.12.018CrossRef

Klippstein R, Wang JTW, El-Gogary RI, Bai J, Mustafa F, Rubio N, Bansal S, Al-Jamal WT, Al-Jamal KT (2015) Passively targeted curcumin-loaded pegylated PLGA nanocapsules for colon cancer therapy in vivo. Small 11(36):4704–4722. https://doi.org/10.1002/smll.201403799CrossRef

Kumar SSD, Rajendran NK, Houreld NN, Abrahamse H (2018) Recent advances on silver nanoparticle and biopolymer-based biomaterials for wound healing applications. Int J Biol Macromol 115(2017):165–75. https://doi.org/10.1016/j.ijbiomac.2018.04.003

Lechuga-Ballesteros D, Abdul-Fattah A, Stevenson CL, Bennett DB (2003) Properties and stability of a liquid crystal form of cyclosporine—the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J Pharm Sci 92(9):1821–1831. https://doi.org/10.1002/jps.10444CrossRef

Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 834(June):188–196CrossRef

Li S-D, Huang L (2008) Reviews pharmacokinetics and biodistribution of nanoparticles

Li W, Zhou J, Xu Y (2015) Study of the in vitro cytotoxicity testing of medical devices (review). 617–620. https://doi.org/10.3892/br.2015.481

Li M, Chunyang D, Guo N, Teng Y, Meng X, Sun H, Li S, Peng Y, Galons H (2019) Composition design and medical application of liposomes. Eur J Med Chem 164:640–653. https://doi.org/10.1016/j.ejmech.2019.01.007CrossRef

Limayem I, Charcosset C, Fessi H (2004) Purification of nanoparticle suspensions by a concentration/diafiltration process. 38:1–9. https://doi.org/10.1016/j.seppur.2003.10.002

Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675–693CrossRef

Madheswaran T, Kandasamy M, Bose RJC, Karuppagounder V (2019) Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discovery Today 24(7):1405–1412. https://doi.org/10.1016/j.drudis.2019.05.004CrossRef

Malik P, Mukherjee TK (2018) Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. Int J Pharm 553(1–2):483–509. https://doi.org/10.1016/j.ijpharm.2018.10.048CrossRef

Malinoski FJ (2014) The nanomedicines alliance: an industry perspective on nanomedicines. Nanomed Nanotechnol Biol Med 10(8):1819–20. https://doi.org/10.1016/j.nano.2014.07.003

Matjaž MG, Škarabot M, Gašperlin M, Janković B (2019) Lamellar liquid crystals maintain keratinocytes’ membrane fluidity: an AFM qualitative and quantitative study. Int J Pharm 572:118712. https://doi.org/10.1016/j.ijpharm.2019.118712CrossRef

Merdan T, Kopeček J, Kissel T (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54:715–758. https://doi.org/10.1016/S0169-409X(02)00046-7CrossRef

Mofokeng TP, Moloto MJ, Shumbula PM, Tetyana P (2019) Synthesis, characterization and cytotoxicity of alanine-capped CuS nanoparticles using human cervical carcinoma HeLa cells. Anal Biochem 580(June):36–41. https://doi.org/10.1016/j.ab.2019.06.008CrossRef

Morshed N, Jahan N, Penheiro DE(2018) Polymeric nanoparticles for targeted delivery in cancer treatment: an overview. Int J Pharm Sci Rev Res 52(1):101–11. http://globalresearchonline.net/journalcontents/v52-1/19.pdf%0A http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=624202638

Müller-Goymann CC (2004) Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 58(2):343–356. https://doi.org/10.1016/j.ejpb.2004.03.028CrossRef

Nance E (2019) Careers in nanomedicine and drug delivery. Adv Drug Deliv Rev. https://doi.org/10.1016/j.addr.2019.06.009CrossRef

Nedyalkova M, Donkova B, Romanova J, Tzvetkov G, Madurga S, Simeonov V (2017) Iron oxide nanoparticles—in vivo/in vitro biomedical applications and in silico studies. Adv Coll Interface Sci 249(February):192–212. https://doi.org/10.1016/j.cis.2017.05.003CrossRef

Neuhaus B, Tosun B, Rotan O, Frede A, Westendorf AM, Epple M (2016) Nanoparticles as transfection agents: a comprehensive study with ten different cell lines. RSC Advances 6(22):18102–18112. https://doi.org/10.1039/c5ra25333kCrossRef

Niu Y, Zhu J, Li Y, Shi H, Gong Y, Li R, Huo Q, Ma T, Liu Y (2018) Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. J Controlled Release 277:35–47. https://doi.org/10.1016/j.jconrel.2018.03.012CrossRef

O’Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17):5421–5426. https://doi.org/10.1046/j.1432-1327.2000.01606.xCrossRef

Pantaleão C, Luchs A (2010) Câncer e modelos experimentais de tumores murinos cancer and experimental models of mouse tumor. Rev Inst Adolfo Lutz 69(4):439–445

Patil YP, Jadhav S (2014) Novel methods for liposome preparation. Chem Phys Lipid 177:8–18. https://doi.org/10.1016/j.chemphyslip.2013.10.011CrossRef

Pena-Pereira F, Lavilla I, Bendicho C (2017) Unmodified gold nanoparticles for in-drop plasmonic-based sensing of iodide. Sens Actuators, B 242:940–948. https://doi.org/10.1016/j.snb.2016.09.161CrossRef

Petrilli R, Eloy J, Marchetti J, Lopez R, Lee R (2014) Targeted lipid nanoparticles for antisense oligonucleotide delivery. Curr Pharm Biotechnol 15(9):847–855. https://doi.org/10.2174/1389201015666141020155834CrossRef

Petrilli R, Eloy JO, Praça FSG, Del Ciampo JO, Fantini MAC, Fonseca MJV, Bentley MVLB (2016a) Liquid crystalline nanodispersions functionalized with cell-penetrating peptides for topical delivery of short-interfering RNAs: a proposal for silencing a pro-inflammatory cytokine in cutaneous diseases. J Biomed Nanotechnol 12(5):1063–1075. https://doi.org/10.1166/jbn.2016.2211CrossRef

Petrilli R, Eloy J, Lopez R, Lee R (2016b) Cetuximab immunoliposomes enhance delivery of 5-FU to skin squamous carcinoma cells. Anticancer Agents Med Chem 17(2):301–308. https://doi.org/10.2174/1871520616666160526110913CrossRef

Petrilli R, Eloy J, Lopez R, Lee R (2017) Cetuximab immunoliposomes enhance delivery of 5-FU to skin squamous carcinoma cells. Anticancer Agents Med Chem 17(2):301–308. https://doi.org/10.2174/1871520616666160526110913CrossRef

Petrilli R, Eloy JO, Saggioro FP, Chesca DL, Claro M, de Souza MVS, Dias LLP, daSilva R, Lee J, Lopez RFV (2018) Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Controlled Release 283(June):151–162. https://doi.org/10.1016/j.jconrel.2018.05.038CrossRef

Praça FS, Garcia WS, Medina G, Petrilli R, Bentley MVLB (2012) Liquid crystal nanodispersions enable the cutaneous delivery of photosensitizer for topical PDT: fluorescence microscopy study of skin penetration. Curr Nanosci 8(4):535–540. https://doi.org/10.2174/157341312801784203CrossRef

Priyadarshini E, Pradhan N (2017) Gold nanoparticles as efficient sensors in colorimetric detection of toxic metal ions: a review. Sens Actuators, B 238:888–902. https://doi.org/10.1016/j.snb.2016.06.081CrossRef

Rai M, Yadav A, Gade A (2009) Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 27(1):76–83. https://doi.org/10.1016/j.biotechadv.2008.09.002CrossRef

Rito C, Pineiro-Maceira J (2009) Microscopia confocal reflectante aplicada ao diagnóstico do. 636–642

Roca AG, Gutiérrez L, Gavilán H, Brollo MEF, Veintemillas-Verdaguer S, del Puerto Morales M (2019) Design strategies for shape-controlled magnetic iron oxide nanoparticles. Adv Drug Deliv Rev 138:68–104. https://doi.org/10.1016/j.addr.2018.12.008

Romero G, Estrela-Lopis I, Zhou J, Rojas E, Franco A, Espinel CS, Gonza A, Gao C, Donath E, Moya SE (2010) Surface engineered poly (lactide-co-glycolide) nanoparticles for intracellular delivery : uptake and cytotoxicity s a confocal raman microscopic study. 2993–2999

Seidi F, Jenjob R, Phakkeeree T, Crespy D (2018) Saccharides, oligosaccharides, and polysaccharides nanoparticles for biomedical applications. J Controlled Release 284(June):188–212. https://doi.org/10.1016/j.jconrel.2018.06.026CrossRef

Seo S-J, Chen M, Wang H, Sil M, Leong KW, Kim H-W (2017) Nano today extra- and intra-cellular fate of nanocarriers under dynamic interactions with biology. Nano Today 14:84–99CrossRef

Severino P, Santana MHA, Souto EB, de Ciências F (2011) Polímeros usados como sistemas de transporte de princípios ativos

Shah M, Badwaik V, Kherde Y, Waghwani HK, Modi T, Aguilar ZP (2014) Table of contents 1. (8):1320–1344

Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M, Kajitani K, Okada M (2015) The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer 15(2):110–116. https://doi.org/10.1016/j.clbc.2014.09.010CrossRef

Simon J, Flahaut E, Golzio M (2019) Overview of carbon nanotubes for biomedical applications. Materials 12(4):1–21. https://doi.org/10.3390/ma12040624CrossRef

Singh S (2000) Phase transitions in liquid crystals. Phys Rep 324(2–4):107–269. https://doi.org/10.1016/S0370-1573(99)00049-6CrossRef

Singh R, Sharma G, Agrawal P, Sonali BP, Koch B, Muthu M (2016) Transferrin receptor targeted PLA-TPGS micelles improved efficacy and safety in docetaxel delivery. Int J Biol Macromol 83:335–344CrossRef

Sittampalam G, Coussens N, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M et al (2016) Assay guidance manual. Assay Guidance Manual Md:305–36. https://doi.org/PMID:22553881

Sjögren G, Sletten G (2000) Cytotoxicity of dental alloys, metals, and ceramics assessed by millipore filter, agar overlay, and MTT tests

Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release. https://doi.org/10.1067/mpr.2000.107227CrossRef

Stepanenko AA, Dmitrenko VV (2015) Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene 574(2):193–203. https://doi.org/10.1016/j.gene.2015.08.009CrossRef

Stockert JC, Horobin RW, Colombo LL, Blázquez-Castro A (2018) Tetrazolium salts and formazan products in cell biology : viability assessment, Fl uorescence imaging, and labeling perspectives. Acta Histochem no February

Sun Q, Ojha T, Kiessling F, Lammers T, Shi Y (2017) Enhancing tumor penetration of nanomedicines. Biomacromol 18(5):1449–1459. https://doi.org/10.1021/acs.biomac.7b00068CrossRef

Tran S, DeGiovanni P-J, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 6(1). https://doi.org/10.1186/s40169-017-0175-0

Valdiglesias V, Fernández-Bertólez N, Kiliç G, Costa C, Costa S, Fraga S, Bessa MJ, Pásaro E, Teixeira JP, Laffon B (2016) Are iron oxide nanoparticles safe? Current knowledge and future perspectives. J Trace Elem Med Biol 38:53–63. https://doi.org/10.1016/j.jtemb.2016.03.017CrossRef

Van de Ven H, Paulussen C, Feijens PB, Matheeussen A, Rombaut P, Kayaert P, Van Den Mooter G (2012) PLGA Nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to fungizone and am bisome. J Controlled Release 161(3):795–803. https://doi.org/10.1016/j.jconrel.2012.05.037CrossRef

Villanueva-García M, Gutiérrez-Parra RN, Martínez-Richa A, Robles J (2005) Quantitative structure-property relationships to estimate nematic transition temperatures in thermotropic liquid crystals. J Mol Struct (Theochem) 727(1–3 SPEC. ISS.):63–69. https://doi.org/10.1016/j.theochem.2005.02.033

Vladisavljević GT (2019) Preparation of microemulsions and nanoemulsions by membrane emulsification. Colloids Surf, A 579:123709. https://doi.org/10.1016/j.colsurfa.2019.123709CrossRef

Wang Y, Huang H-Y, Yang L, Zhang Z, Ji H (2016) Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Nature Publishing Group no May:1–10. https://doi.org/10.1038/srep25468

Wei L, Guo XY, Yang T, Min Zhi Y, Chen DW, Wang JC (2016) Brain tumor-targeted therapy by systemic delivery of SiRNA with transferrin receptor-mediated core-shell nanoparticles. Int J Pharm 510(1):394–405. https://doi.org/10.1016/j.ijpharm.2016.06.127CrossRef

Wolfram J, Ferrari M (2019) Clinical cancer nanomedicine. Nano Today 25:85–98. https://doi.org/10.1016/j.nantod.2019.02.005CrossRef

Xiao B, Han MK, Viennois E, Wang L, Zhang M, Si X, Merlin D (2015a) Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale 7(42):17745–17755. https://doi.org/10.1039/c5nr04831aCrossRef

Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT, Jung Y, Merlin D (2015b) Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials 48:147–160. https://doi.org/10.1016/j.biomaterials.2015.01.014CrossRef

Xu ZP, Zeng QH, Lu GQ, Yu AB (2006) Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 61(3):1027–1040. https://doi.org/10.1016/j.ces.2005.06.019CrossRef

Xue Y (2016) Carbon nanotubes for biomedical applications. Industrial applications of carbon nanotubes. Elsevier Inc., Amsterdam. https://doi.org/10.1016/B978-0-323-41481-4.00011-3CrossRef

Yazdimamaghani M, Moos PJ, Dobrovolskaia MA, Ghandehari H (2019) Genotoxicity of amorphous silica nanoparticles: status and prospects. Nanomed: Nanotechnol Biol Med 16(xxxx):106–25. https://doi.org/10.1016/j.nano.2018.11.013

Yeh YC, Creran B, Rotello VM (2012) Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale 4(6):1871–1880. https://doi.org/10.1039/c1nr11188dCrossRef

Zorko M, Langel U (2005) Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57:529–545CrossRef

Titel: Nanotechnology: Concepts and Potential Applications in Medicine
verfasst von: Luiziana Cavalcante Costa Fernandes
Karina Alexandre Barros Nogueira
Jéssica Roberta Pereira Martins
Elias Santos
Paulo George Cavalcante de Freitas
Beatriz Alexandre Barros Nogueira
Giovanni Loureiro Raspantini
Raquel Petrilli
Josimar O. Eloy
Verlag: Springer Singapore
Buch: Nanomaterials and Nanotechnology
Print ISBN: 978-981-336-055-6

Electronic ISBN: 978-981-336-056-3

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-981-33-6056-3_1

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht